BACKGROUND Recent reports suggest an elevated incidence of bioresorbable vascular scaffold (BVS) thrombosis
Scaffold Stents) (6) provided data in support of the safety of BVS, an unexpectedly high incidence of scaffold thrombosis (ScT) has been reported in single-center and multicenter observational studies (7-10) and in a recently published meta-analysis (11) .
In particular, the 6-month incidence of ScT was 2% in the GHOST-EU (Gauging coronary Healing with biOresorbable Scaffolding platforms in EUrope) registry (7) and was as high as 3% in the academic medical center single-center registry (8) . In the BVS EXAMINATION trial, a propensity score-matched analysis of ST-segment elevation myocardial infarction (STEMI) patients, a tendency toward higher rates of early ScT was observed in patients who received BVS compared with DES or baremetal stents. Rates at 1 month were 2.1% for BVS, 0.3% for DES, and 1.0% for bare-metal stents (p ¼ 0.06 for BVS vs. DES) (12) .
The existence of clinical or procedural predictors of ScT, and whether this incidence can be addressed, are unknown. The aim of this study was to describe the incidence and clinical presentation of ScT and to identify its clinical and procedural predictors in a large all-comer population. follow-up at regular, pre-scheduled intervals. These data were acquired locally by trained medical staff using standardized questionnaires via clinical visits and through telephone contacts. Referring cardiologists, general practitioners, and patients were contacted whenever necessary for further information. All data were then internally audited in each center by staff who were not involved in data entry (T.G., M.W.), and they were retrospectively entered in the multicentric database in an anonymized way according to national privacy policies and laws and following the requirements of the ethics committee of the University Medical Center Mainz. Data were audited again centrally for consistency and plausibility, and queries were generated when necessary. There were 36 definite, 4 probable, and 2 possible ScT ( Figure 1B) . A total of 21 ScTs (50%) occurred early, of which 10 (24%) were "acute" or within 1 day, 11 (26%) were "subacute" or within 1 month, 11 (26%) Tables 2 to 10 ).
METHODS
MLD ¼ minimum lumen diameter; RVD ¼ reference vessel diameter; other abbreviations as in Tables 1 and 2. were late, and 10 (24%) were very late. The median duration from implantation to ScT was 26 days (IQR: 4 to 212 days). The curve describing the incidence of
ScT showed an initial peak within the first 30 days, followed by a more diffuse distribution in the following months. Overall, the Kaplan-Meier incidence was 1.8% at 30 days, 2.3% at 6 months, and Table 1 . The results of the Cox analysis are shown in Table 2 . When ScT patients with premature DAPT interruption were excluded, the results of the univariable and multivariable analysis did not differ substantially.
QCA ANALYSIS. The QCA was conducted using a nested case-control design in the 42 ScT patients (42 lesions) and 84 matched control subjects (84 lesions). At baseline, lesion length, pre-PCI TIMI flow rate, MLD, and % stenosis were similar between the groups (Online Table 1 ). RVD was significantly larger in the control subjects. After implantation, significant differences were found for RVD and MLD, which were lower in the ScT group ( Table 3) . The residual stenosis was comparable between the groups, but when this parameter was corrected by the nominal BVS diameter ("residual scaled stenosis,"
expressing the degree of deployment of the BVS compared with its nominal value), the difference between groups was highly significant. Similarly, the MLD-derived maximum footprint ( Figure 3 ) was significantly larger in the ScT group (Online Table 1 ).
In multivariable analyses ( Table 3, Online Tables 2   to 10 A number of clinical or procedural characteristics showed relevant differences between the 2 groups (Online Tables 11 and 12 ); however, none of these, except for ostial lesions, was associated with ScT (Table 4) . In contrast, the implantation protocol used ("early experience" versus "BVS-specific implantation protocol" group) was independently associated with a significant (w70%) reduction in the incidence of ScT (p ¼ 0.035). This result was confirmed by the propensity score analysis (p ¼ 0.012).
DISCUSSION
The key findings of this all-comer, multicentric registry study are: 1) similar to DES, ScT is a particularly severe complication whose 12-month incidence was as high as 3% unless meticulous attention was paid at the ScT. ROC analysis applied to MLD data suggest that a 
